Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IBRX
#912
ImmunityBio, Inc. - Common Stock
7.5
2
USD
-2.59%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-2.59%
Monthly Change
+7.58%
6 month change
+214.64%
Year Change
+184.85%
Previous Close
7.7
2
Open
7.5
2
Low
7.5
2
High
7.5
2
Volume
155
Markets
US Stock Market
Healthcare
IBRX
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
109.34 M
397.91 M
435.84 M
673.95 M
853.44 M
1.03 B
1.05 B
Valuation ratios
Enterprise value
—
2.24 B
1.97 B
4.1 B
2.33 B
2.27 B
7.83 B
Price to earnings ratio
—
-6.83
-4.59
-4.56
-4.13
-5.21
-8.57
Price to sales ratio
—
2 533.77
7 948.02
4 284.97
121.61
16.08
49.13
Price to cash flow ratio
—
-8.62
-5.65
-7.27
-4.58
-5.97
-23.31
Price to book ratio
—
-9.77
-4.26
-4.54
-3.67
-3.64
-2.82
Enterprise value to EBITDA ratio
—
-7.09
-5.94
-11.94
-7.12
-9.46
-31.92
Profitability ratios
Return on assets %
-0.61
-0.74
-1.15
-1.16
-1.08
-0.7
-0.98
Return on equity %
-0.79
1.42
0.93
1
0.85
0.7
0.73
Return on invested capital %
-413.84
-499.16
-255.34
-327.6
-630.3
-482.33
-129.91
Gross margin %
100
100
100
100
100
99.34
99.46
Operating margin %
-82.55 K
-35.36 K
-146.37 K
-58.24 K
-2 334.23
-226
-157.88
EBITDA margin %
-74.31 K
-33.84 K
-138.77 K
-55.26 K
-2 215.18
-212.29
-147.97
Net margin %
-83.23 K
-37.13 K
-173.57 K
-93.76 K
-2 804.77
-310.18
-1 431.44
Liquidity ratios
Quick ratio
—
—
—
—
3.21
5.08
6.66
Current ratio
3.06
0.91
0.28
5.05
3.36
5.1
6.67
Inventory turnover
—
—
—
—
0
0.83
0.33
Asset turnover
0
0
0
0
0.03
0.23
0.08
Solvency ratios
Debt to assets ratio
—
—
—
1.66
0.74
0.65
0.63
Debt to equity ratio
—
—
—
-1.43
-0.58
-0.65
-0.47
Long term debt to total assets ratio
—
—
-0.18
1.66
0.74
0.65
0.63
Long term debt to total equity ratio
—
—
0.14
-1.43
-0.58
-0.65
-0.46
Per share metrics
Operating cash flow per share
—
-0.71
-0.84
-0.72
-0.56
-0.33
-0.31
EBIT per share
—
-0.85
-0.88
-0.71
-0.49
-0.28
-0.28
EBITDA per share
—
-0.81
-0.83
-0.68
-0.47
-0.26
-0.26
Total debt per share
—
—
—
1.65
0.41
0.35
0.39
Cash per share
—
0.81
0.27
0.52
0.21
0.26
0.37
Net current asset value per share
—
0.86
0.35
0.58
0.26
0.34
0.44
Tangible book value per share
—
-0.62
-1.12
-1.15
-0.72
-0.56
-0.86
Working capital per share
—
-0.09
-0.9
0.46
0.19
0.28
0.37
Book value per share
—
-0.62
-1.12
-1.15
-0.7
-0.54
-0.85
News
IBRX and the BCG Shortage: Deals That Could Expand Demand
IBRX Stock Outlook After Q1 Results and a New FDA Review
ImmunityBio: Anktiva Explained and What Comes Next
Undercovered Stocks: Cerebras Systems, Infleqtion, Duos Technologies And More
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer
ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM (IBRX)
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Why ImmunityBio Stock Is Surging On Wednesday? - ImmunityBio (NASDAQ:IBRX)
ImmunityBio to Report Q1 Earnings: What's in the Cards?
IBRX Global Rollout: EU, MENA, and Asia Shape 2026-27 Catalysts
Is IBRX Priced for Perfection at Nearly 28x Forward Sales?